DK0755249T3 - Anvendelse af Maillard-reaktionsinhibitor til behandling af amyloidose-baseret sygdom - Google Patents
Anvendelse af Maillard-reaktionsinhibitor til behandling af amyloidose-baseret sygdomInfo
- Publication number
- DK0755249T3 DK0755249T3 DK95915254T DK95915254T DK0755249T3 DK 0755249 T3 DK0755249 T3 DK 0755249T3 DK 95915254 T DK95915254 T DK 95915254T DK 95915254 T DK95915254 T DK 95915254T DK 0755249 T3 DK0755249 T3 DK 0755249T3
- Authority
- DK
- Denmark
- Prior art keywords
- maillard reaction
- reaction inhibitor
- based disease
- treat amyloidosis
- amyloidosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9407305A GB2288732B (en) | 1994-04-13 | 1994-04-13 | Pharmaceutical compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0755249T3 true DK0755249T3 (da) | 2004-07-26 |
Family
ID=10753465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK95915254T DK0755249T3 (da) | 1994-04-13 | 1995-04-13 | Anvendelse af Maillard-reaktionsinhibitor til behandling af amyloidose-baseret sygdom |
Country Status (11)
Country | Link |
---|---|
US (2) | US5891873A (de) |
EP (1) | EP0755249B1 (de) |
JP (1) | JPH09512005A (de) |
AT (1) | ATE262895T1 (de) |
AU (1) | AU2219795A (de) |
DE (1) | DE69532804T2 (de) |
DK (1) | DK0755249T3 (de) |
ES (1) | ES2216012T3 (de) |
GB (1) | GB2288732B (de) |
PT (1) | PT755249E (de) |
WO (1) | WO1995028151A1 (de) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6673335B1 (en) * | 1992-07-08 | 2004-01-06 | Nektar Therapeutics | Compositions and methods for the pulmonary delivery of aerosolized medicaments |
US6582728B1 (en) * | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
ES2179831T3 (es) * | 1992-09-29 | 2003-02-01 | Inhale Therapeutic Syst | Liberacion en los pulmones de fragmentos activos de hormona paratiroidiana. |
US20030113273A1 (en) * | 1996-06-17 | 2003-06-19 | Patton John S. | Methods and compositions for pulmonary delivery of insulin |
ES2316917T3 (es) * | 1994-03-07 | 2009-04-16 | Nektar Therapeutics | Metodos y composiciones para suministro pulmonar de insulina. |
GB2288732B (en) * | 1994-04-13 | 1998-04-29 | Quadrant Holdings Cambridge | Pharmaceutical compositions |
MX9605717A (es) * | 1994-05-18 | 1998-05-31 | Inhale Therapeutic Syst | Metodos y composiciones para la formulacion de polvo seco de interferones. |
US6290991B1 (en) | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
US6512010B1 (en) | 1996-07-15 | 2003-01-28 | Alza Corporation | Formulations for the administration of fluoxetine |
US5780513A (en) * | 1996-08-22 | 1998-07-14 | Washington University | Method of inhibiting the release of bioactive IL-1 |
US6203817B1 (en) | 1997-02-19 | 2001-03-20 | Alza Corporation | Reduction of skin reactions caused by transdermal drug delivery |
US20030035778A1 (en) * | 1997-07-14 | 2003-02-20 | Robert Platz | Methods and compositions for the dry powder formulation of interferon |
JPH1143432A (ja) * | 1997-07-25 | 1999-02-16 | Biremo Sci:Kk | 脳の老化抑制及び治療剤 |
US6309623B1 (en) * | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
EP1053749A4 (de) * | 1998-02-03 | 2003-01-15 | Senju Pharma Co | Vorbeuge- und heilmittel für neurodegenerative erkrankungen |
GB9916316D0 (en) | 1999-07-12 | 1999-09-15 | Quadrant Holdings Cambridge | Dry powder compositions |
JP2003531570A (ja) * | 1999-07-27 | 2003-10-28 | アブジェニックス インク. | 神経障害に関連したポリペプチド蓄積を阻害する方法および組成物 |
US8404217B2 (en) | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
AU6124601A (en) | 2000-05-10 | 2001-11-20 | Alliance Pharmaceutical Corporation | Phospholipid-based powders for drug delivery |
AU2001280934A1 (en) * | 2000-07-28 | 2002-02-13 | Alliance Pharmaceutical Corp. | Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds |
US7368102B2 (en) | 2001-12-19 | 2008-05-06 | Nektar Therapeutics | Pulmonary delivery of aminoglycosides |
CA2607663C (en) * | 2005-05-19 | 2014-08-12 | Amgen Inc. | Compositions and methods for increasing the stability of antibodies |
EP1893576A4 (de) * | 2005-05-27 | 2010-03-17 | Univ Kingston | Behandlung von proteinfaltungsstörungen |
US20070031342A1 (en) * | 2005-06-22 | 2007-02-08 | Nektar Therapeutics | Sustained release microparticles for pulmonary delivery |
CL2007002880A1 (es) * | 2006-10-06 | 2008-05-09 | Amgen Inc | Formulacion estable que comprende un tampon de acido acetico, un tampon de acido glutamico o un tampon de acido succinico con un ph de 4,5 a 7, por lo menos un excipiente que comprende un azucar o un poliol, y un anticuerpo anti-receptor del factor d |
US7705132B2 (en) * | 2006-10-20 | 2010-04-27 | Amgen Inc. | Stable polypeptide formulations |
WO2018225623A1 (ja) | 2017-06-07 | 2018-12-13 | 天野エンザイム株式会社 | ラクターゼ原末及びラクターゼ製剤 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0325936A3 (de) * | 1988-01-16 | 1990-01-17 | Ono Pharmaceutical Co., Ltd. | Aminoguanidin-Derivate und für die Maillardreaktion inhibitorische Substanzen, die sie als aktive Inhaltsstoffe enthalten |
JPH03161441A (ja) * | 1989-11-20 | 1991-07-11 | Senjiyu Seiyaku Kk | メイラード反応阻害剤 |
JP2854631B2 (ja) * | 1989-11-21 | 1999-02-03 | 千寿製薬株式会社 | 糖尿病合併症および老化によって引き起こされる疾患の予防・治療剤 |
IL110622A (en) * | 1989-11-28 | 1995-03-30 | Syntex Inc | N-cyclic carboxamides are converted by cyclic amines |
EP0474874B1 (de) * | 1990-02-19 | 1995-10-18 | Senju Pharmaceutical Co., Ltd. | Zusammensetzungen von Maillard-Reaktion inhibitoren |
PT96930B (pt) * | 1990-03-02 | 1998-06-30 | Univ Oregon | Metodo para a utilizacao de guanidinas tri- e tetra-substituidas como antagonistas de amino-acidos excitadores |
US5112596A (en) * | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
PT100115B (pt) * | 1991-02-08 | 1999-06-30 | Cambridge Neuroscience Inc | Guanidinas substituidas e seus derivados uteis como moduladores de libertacao de neurotransmissores e ensaios de rastreio para de bloqueadores de libertacao de neurotransmissores |
TW221689B (de) * | 1991-08-27 | 1994-03-11 | Otsuka Pharma Co Ltd | |
US5453514A (en) * | 1992-12-25 | 1995-09-26 | Yamanouchi Pharmaceutical Co., Ltd. | Pyrazole derivatives and compositions and methods of use as maillard reaction inhibitors |
US5935927A (en) * | 1994-02-03 | 1999-08-10 | The Picower Institute For Medical Research | Compositions and methods for stimulating amyloid removal in amyloidogenic diseases using advanced glycosylation endproducts |
GB2288732B (en) * | 1994-04-13 | 1998-04-29 | Quadrant Holdings Cambridge | Pharmaceutical compositions |
-
1994
- 1994-04-13 GB GB9407305A patent/GB2288732B/en not_active Revoked
-
1995
- 1995-04-13 DK DK95915254T patent/DK0755249T3/da active
- 1995-04-13 US US08/727,597 patent/US5891873A/en not_active Expired - Lifetime
- 1995-04-13 WO PCT/GB1995/000843 patent/WO1995028151A1/en active IP Right Grant
- 1995-04-13 DE DE69532804T patent/DE69532804T2/de not_active Expired - Fee Related
- 1995-04-13 ES ES95915254T patent/ES2216012T3/es not_active Expired - Lifetime
- 1995-04-13 EP EP95915254A patent/EP0755249B1/de not_active Expired - Lifetime
- 1995-04-13 AU AU22197/95A patent/AU2219795A/en not_active Abandoned
- 1995-04-13 AT AT95915254T patent/ATE262895T1/de not_active IP Right Cessation
- 1995-04-13 PT PT95915254T patent/PT755249E/pt unknown
- 1995-04-13 JP JP7526804A patent/JPH09512005A/ja not_active Ceased
-
1998
- 1998-12-04 US US09/205,329 patent/US6034080A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0755249B1 (de) | 2004-03-31 |
EP0755249A1 (de) | 1997-01-29 |
JPH09512005A (ja) | 1997-12-02 |
ES2216012T3 (es) | 2004-10-16 |
DE69532804T2 (de) | 2005-02-10 |
GB2288732B (en) | 1998-04-29 |
PT755249E (pt) | 2004-08-31 |
WO1995028151A1 (en) | 1995-10-26 |
DE69532804D1 (de) | 2004-05-06 |
ATE262895T1 (de) | 2004-04-15 |
US5891873A (en) | 1999-04-06 |
GB9407305D0 (en) | 1994-06-08 |
GB2288732A (en) | 1995-11-01 |
AU2219795A (en) | 1995-11-10 |
US6034080A (en) | 2000-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0755249T3 (da) | Anvendelse af Maillard-reaktionsinhibitor til behandling af amyloidose-baseret sygdom | |
NZ335981A (en) | Ketobenzamides as calpain inhibitors | |
DK0971713T3 (da) | Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser | |
GB0005251D0 (en) | Therapeutic compounds | |
DK1039912T3 (da) | Angiostatiske midler og præparater til behandling af GLC1A-glaukom | |
ATE313326T1 (de) | VERWENDUNG VON CABERGOLIN ZUR BEHANDLUNG VON ßRESTLESS LEGS SYNDROMß | |
NZ517616A (en) | Use of retigabin for treating neuropathic pain | |
DK0705099T3 (da) | Anvendelse af modafinil til behandling af søvnapnø og åndedrætslidelser af central oprindelse | |
DK0739212T3 (da) | Anvendelse af interleukin-12 til forebyggelse af transplantat-vs.-værtssygdom | |
MXPA02002117A (es) | Uso de productos leguminosos para el tratamiento de agresiones externas. | |
PL316656A1 (en) | Free halophantrin base for use in treating marsh-fever and compositions containing same | |
BG101138A (en) | The use of glyceryltriacetate for the treatment of onychomycosis | |
MX9805290A (es) | Utilizacion de inhibidores de la actividad del acido retinoico para tratar las pieles sensibles y/o los daños agudos inducidos por las radiaciones ultravioleta. | |
BR9612283A (pt) | Composição para o tratamento de manchas em peças de roupa e métodos de tratamento | |
TR199900505T2 (de) | ||
PL334498A1 (en) | Application of pramiprexole in treating the restless legs syndrome | |
GB9916729D0 (en) | Fuller for the treatment of leather,pelts and the like | |
ZA9711468B (en) | New use of comt inhibitors | |
DE60235132D1 (de) | Sojaprodukte enthaltende Zusammensetzungen | |
LV11593A (lv) | Dimetikona pielietojums aizcietejumu arstesana | |
IL139144A0 (en) | Mycobacterial inhibitors | |
DK1042288T3 (da) | Tripeptidyl-peptidase inhibitorer | |
DE69906701D1 (de) | Topische verwendung von loperamid zur behandlung mikrobieller infektionen | |
DE69716056D1 (de) | Acylurea-verbindungen zur behandlung von coccidioidomycosis bei warmblütigen tieren | |
BR0012380A (pt) | 2-amino-benzoxazinonas para o tratamento de vìrus do herpes simples |